US Edition
Published • loading... • Updated
Annovis Reports 2025 Results, Advances Buntanetap Trials
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Annovis Reports 2025 Results, Advances Buntanetap Trials
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) reported its 2025 financial results and said it advanced late-stage clinical development of its investigational drug buntanetap, including launching a Phase 3 trial for early Alzheimer’s disease and initiating a Parkinson’s disease extension study. The company announced the updates alongside its fiscal year results. Annovis said it began a pivotal Phase 3 trial in February 2025 evaluating buntanetap in…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
